<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2c66ebff-4389-49f9-a6ed-39d7de46dcb5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use, SODIUM SULFATE, POTASSIUM SULFATE and MAGNESIUM SULFATE ORAL SOLUTION safely and effectively. See full prescribing information for SODIUM SULFATE, POTASSIUM SULFATE and MAGNESIUM SULFATE ORAL SOLUTION.<br/>
      <br/>SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE oral solution, for oral use<br/>Initial U.S. Approval: 2010</title>
   <effectiveTime value="20250312"/>
   <setId root="d48d8c59-68b9-4e28-86a4-eabf8b2003b0"/>
   <versionNumber value="4"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="650738743" root="1.3.6.1.4.1.519.1"/>
            <name>Strides Pharma Science Limited</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3381e0fd-9b99-4ba4-ab6f-1bb673ea9284"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL Product Data Elements Section"/>
               <effectiveTime value="20250312"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="64380-116" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral<suffix/>
                        </name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="17.5" unit="g"/>
                              <denominator value="177" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0YPR65R21J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="36KCS0R750" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SULFATE ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="3.13" unit="g"/>
                              <denominator value="177" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1K573LC5TV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="7IS9N8KPMG" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SULFATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1.6" unit="g"/>
                              <denominator value="177" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="DE08037SAB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM SULFATE, UNSPECIFIED FORM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="T6V3LHY838" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ245FE5EU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BENZOATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCRALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="817L1N4CKP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MALIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="177" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="64380-116-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="64380-116-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240117"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA215469" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240117"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73365" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BERRY" xsi:type="CE">
                              <originalText>MIX BERRY</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID18">
               <id root="e68ebc3d-fdc4-4f1e-be9b-34f0c78342cc"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title>RECENT MAJOR CHANGES</title>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table ID="ID20" width="100%" styleCode="Noautorules">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Toprule Lrule" align="left">
                                    <linkHtml href="#ID#s2"/>Indications and Usage (<linkHtml href="#ID#s2">1</linkHtml>)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Rrule" align="right"> 7/2020<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Lrule Botrule" align="left"> Dosage and Administration (<linkHtml href="#ID#Lae165181-f458-48bb-b026-7eb3d46879c3">2.1</linkHtml>, <linkHtml href="#ID#L74f82ace-2e9f-443f-a731-64f30cce5b37">2.4</linkHtml>)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="right"> 7/2020<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID21">
               <id root="8b8f5489-9c2d-4978-a906-1d947d72eb12"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="ID22">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older.</paragraph>
               </text>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID24">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adult and pediatric patients 12 years of age and older (1).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID25">
               <id root="269166eb-17a1-4d05-9632-4b482c7de118"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID27">
                           <content styleCode="underline">Preparation and Administration (2.2)</content>
                        </paragraph>
                        <list listType="unordered" ID="ID28" styleCode="Disc">
                           <item>Must dilute in water prior to ingestion</item>
                           <item>Administration of two bottles of sodium      sulfate, potassium sulfate and magnesium sulfate oral solution is required      for a complete preparation for colonoscopy. One bottle is equivalent to      one dose.</item>
                           <item>Must consume additional water after      each dose.</item>
                           <item>Stop consumption of all fluids at least      2 hours before the colonoscopy.</item>
                        </list>
                        <paragraph ID="ID154">
                           <content styleCode="underline">Recommended Dosage and Administration</content>
                        </paragraph>
                        <list listType="unordered" ID="ID155" styleCode="Disc">
                           <item>Split-Dose (two-day) regimen consists of two doses of sodium sulfate, potassium sulfate and magnesium sulfate oral solution: first dose during the evening prior to colonoscopy and second dose the next day, during the morning of colonoscopy. (2.1, 2.3, 2.4)</item>
                           <item>Recommended sodium sulfate, potassium sulfate and magnesium sulfate oral solution dosage is:</item>
                           <item>
                              <content styleCode="bold">Adults: </content> Two 6-ounce doses. (2.3)</item>
                           <item>
                              <content styleCode="bold">Pediatric Patients 12 Years of Age and Older: </content> Two 4.5-ounce doses. (2.4)</item>
                           <item>For complete information on preparation before colonoscopy and administration of the dosage regimen, see full prescribing Information. (2.1, 2.2, 2.3, 2.4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID29">
                     <id root="7b46c747-5ba8-40dd-9420-57ae1e0ad567"/>
                     <title>2.1 Dosage and Adminstration Overview</title>
                     <text>
                        <paragraph ID="ID30">Administration of two bottles of sodium sulfate, potassium sulfate and magnesium sulfate oral solution and additional water is required for a complete preparation for colonoscopy. One bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral solution is equivalent to one dose. Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is supplied in two dosage strengths <content styleCode="italics">[see Dosage Forms and Strengths (3)]</content>. The recommended dosage is:</paragraph>
                        <list listType="unordered" ID="ID152" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Adults</content> :      Two 6-ounce doses <content styleCode="italics">[see Dosage and Administration (2.3)]</content> .</item>
                           <item>
                              <content styleCode="bold">Pediatric patients 12 years of age and older: </content> Two      4.5-ounce doses <content styleCode="italics">[see Dosage and Administration (2.4)]</content> .</item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID138">
                     <id root="9d62aae9-4e1c-458c-8b83-fc4e75cda84e"/>
                     <title>2.2 Important Preparation and Administration Instructions</title>
                     <text>
                        <list listType="unordered" ID="ID139" styleCode="Disc">
                           <item>Correct fluid and electrolyte abnormalities before      treatment with sodium sulfate, potassium sulfate and      magnesium sulfate oral solution <content styleCode="italics">[see Warnings and Precautions      (5.1)]</content>
                           </item>
                           <item>Must dilute sodium sulfate, potassium      sulfate and magnesium sulfate oral solution in      water before ingestion.</item>
                           <item>Must consume additional water after each dose of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution.</item>
                           <item>On the day before colonoscopy, consume only a light      breakfast or clear liquids (e.g., water, strained fruit juice without      pulp, lemonade, plain coffee or tea, chicken broth, gelatin dessert      without fruit). On the day of the colonoscopy only consume clear liquids      up to two hours prior to colonoscopy.</item>
                           <item>Do not eat solid food or drink milk or eat or drink      anything colored red or purple.</item>
                           <item>Do not drink alcohol.</item>
                           <item>Do not take other laxatives while taking sodium      sulfate, potassium sulfate and magnesium sulfate oral solution.</item>
                           <item>Do not take oral medications within one hour of starting      each dose of sodium sulfate, potassium sulfate and      magnesium sulfate oral solution.</item>
                           <item>If taking tetracycline or fluoroquinolone antibiotics,      iron, digoxin, chlorpromazine, or penicillamine, take these medications at      least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution <content styleCode="italics">[see Drug Interactions (7.2)]</content> .</item>
                           <item>Stop consumption of all fluids at least 2 hours prior to      the colonoscopy.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID31">
                     <id root="af587da9-d880-4d21-8426-607e1fca27e9"/>
                     <title>2.3 Recommended Dosage and Administration in Adults</title>
                     <text>
                        <paragraph ID="ID32">The recommended Split-Dose (two-day) regimen for <content styleCode="bold">adults </content>consists of two 6-ounce doses of sodium sulfate, potassium sulfate and magnesium sulfate oral solution: the first dose during the evening prior to colonoscopy and the second dose the next day, during the morning of the colonoscopy.</paragraph>
                        <paragraph>Each dose consists of one bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral solution with additional water. The total volume of liquid required for colon cleansing (using two bottles) is 3 quarts. The following are recommended dosage and administration instructions for adults:</paragraph>
                        <paragraph>Dose 1 – On the Day Prior to Colonoscopy:</paragraph>
                        <list listType="unordered" ID="ID33" styleCode="Disc">
                           <item>May consume a light breakfast, or only      clear liquids (no solid food).</item>
                           <item>In the evening before the procedure,      pour the contents of one bottle of sodium sulfate,      potassium sulfate and magnesium sulfate oral solution into the mixing      container provided.</item>
                           <item>Add cool drinking water to the 16-ounce      fill line on the container, mix, and drink the entire amount.</item>
                           <item>Drink two additional containers filled with water to the 16-ounce fill line over the next      hour.</item>
                        </list>
                        <paragraph ID="ID34">Dose 2 - Day of Colonoscopy:</paragraph>
                        <list listType="unordered" ID="ID35" styleCode="Disc">
                           <item>Continue to consume only clear liquids.</item>
                           <item>In the morning (10 to 12 hours after      the evening dose) on the day of the procedure, pour the contents of the      second bottle of sodium sulfate, potassium sulfate      and magnesium sulfate oral solution into the mixing container provided.</item>
                           <item>Add cool drinking water to the 16-ounce      fill line on the container, mix, and drink the entire amount.</item>
                           <item>Drink two additional containers filled      with water to the 16-ounce fill line over the next hour.</item>
                           <item>Complete all solution of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution and required water at least two hours prior to colonoscopy.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID156">
                     <id root="ca511623-e102-44a3-aa5c-f2c44b49ee14"/>
                     <title>2.4 Recommended Dosage and Administration in Pediatric Patients 12 Years of Age and Older</title>
                     <text>
                        <paragraph ID="ID157">The recommended Split-Dose (two-day) regimen <content styleCode="bold">for</content> <content styleCode="bold">pediatric patients 12 years of age and older</content> consists of two 4.5-ounce doses of sodium sulfate, potassium sulfate and magnesium sulfate oral solution: the first dose during the evening prior to colonoscopy and the second dose the next day, during the morning of the colonoscopy.</paragraph>
                        <paragraph>Each dose consists of one bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral solution with additional water. The total volume of liquid required for colon cleansing (using two bottles) is 2.25 quarts. The following are recommended dosage and administration instructions for pediatric patients 12 years of age and older and/or their caregivers:</paragraph>
                        <paragraph>Dose 1 – On the Day Prior to Colonoscopy:</paragraph>
                        <list listType="unordered" ID="ID158" styleCode="Disc">
                           <item>May consume a light breakfast, or only clear liquids (no      solid food).</item>
                           <item>In the evening before the procedure, pour the contents of      one bottle of sodium sulfate, potassium sulfate and      magnesium sulfate oral solution into the mixing container provided.</item>
                           <item>Add cool drinking water to the 12-ounce fill line on the      container, mix, and drink the entire amount.</item>
                           <item>Drink two additional containers filled with water to the      12-ounce fill line over the next hour.</item>
                        </list>
                        <paragraph ID="ID159">Dose 2 – Day of Colonoscopy:</paragraph>
                        <list listType="unordered" ID="ID160" styleCode="Disc">
                           <item>Continue to consume only clear liquids.</item>
                           <item>In the morning (10 to 12 hours after the evening dose) on      the day of the procedure, pour the contents of the second bottle of sodium      sulfate, potassium sulfate and magnesium sulfate oral      solution into the mixing container provided.</item>
                           <item>Add cool drinking water to the 12-ounce fill line on the      container, mix, and drink the entire amount.</item>
                           <item>Drink two additional containers filled with water to the      12-ounce fill line over the next hour.</item>
                           <item>Complete all solution of sodium sulfate,      potassium sulfate and magnesium sulfate oral solution and      required water at least two hours prior to colonoscopy.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID36">
               <id root="0c6bce2d-0c0a-4d18-8b44-dbeb31965070"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="ID38">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution <content styleCode="bold">(for adults)</content>: Two bottles each containing 6 ounces of an oral solution of 17.5 grams sodium sulfate, 3.13 grams potassium sulfate, and 1.6 grams magnesium sulfate as a clear to slightly hazy liquid.</paragraph>
                  <paragraph>When diluted as directed, the solution is clear and colorless.</paragraph>
               </text>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID40" styleCode="Disc">
                           <item>Sodium sulfate, potassium sulfate and      magnesium sulfate oral solution <content styleCode="bold">(for adults)</content> : Two bottles each      containing 6 ounces of an oral solution of 17.5 grams sodium sulfate, 3.13      grams potassium sulfate, and 1.6 grams magnesium sulfate. (3)   </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID140">
               <id root="196bf24e-ba40-420f-a128-2fb0d0ec8f3f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="ID141">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is contraindicated in the following conditions:</paragraph>
                  <list listType="unordered" ID="ID142" styleCode="Disc">
                     <item>Gastrointestinal obstruction or ileus <content styleCode="italics">[see Warnings and      Precautions (5.6)]</content>
                     </item>
                     <item>Bowel perforation <content styleCode="italics">[see Warnings and Precaution (5.6)]</content>
                     </item>
                     <item>Toxic colitis or toxic megacolon</item>
                     <item>Gastric retention</item>
                     <item>Hypersensitivity to any of the ingredients in sodium sulfate, potassium sulfate and magnesium sulfate oral      solution</item>
                  </list>
               </text>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID144" styleCode="Disc">
                           <item>Gastrointestinal obstruction or ileus      (4,5.6)</item>
                           <item>Bowel perforation (4, 5.6)</item>
                           <item>Toxic colitis or toxic megacolon (4)</item>
                           <item>Gastric retention (4)</item>
                           <item>Hypersensitivity to any ingredient (4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID41">
               <id root="411a6f93-c624-4966-8529-8fc6b16b9311"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240117"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="ID151" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Risk of fluid and electrolyte abnormalities</content> : Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after each use. (5.1, 7.1)</item>
                           <item>
                              <content styleCode="underline">Cardiac arrhythmias</content> : Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. (5.2)</item>
                           <item>
                              <content styleCode="underline">Seizures</content> : Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold. (5.3, 7.1)</item>
                           <item>
                              <content styleCode="underline">Patients with renal impairment or taking concomitant medications that affect renal function</content> : Use caution, ensure adequate hydration and consider laboratory testing. (5.4, 7.1)</item>
                           <item>
                              <content styleCode="underline">Suspected GI obstruction or perforation:</content> Rule out the diagnosis before administration. (4, 5.6)</item>
                           <item>
                              <content styleCode="underline">Patients at risk for aspiration</content> : Observe during administration. (5.7)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID42">
                     <id root="c4ca3f14-32fa-44eb-b35d-efe870ca8fd2"/>
                     <title>5.1 Serious Fluid and Serum Chemistry Abnormalities</title>
                     <text>
                        <paragraph ID="ID43">Advise all patients to hydrate adequately before, during, and after the use of sodium sulfate, potassium sulfate and magnesium sulfate oral solution. If a patient develops significant vomiting or signs of dehydration after taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN).</paragraph>
                        <paragraph>Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Correct fluid and electrolyte abnormalities before treatment with sodium sulfate, potassium sulfate and magnesium sulfate oral solution. Use sodium sulfate, potassium sulfate and magnesium sulfate oral solution with caution in patients with conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment <content styleCode="italics">[see Drug Interactions (7.1)]</content>. </paragraph>
                        <paragraph>Sodium sulfate, potassium sulfate and magnesium sulfate oral solution can cause temporary elevations in uric acid. [<content styleCode="italics">See Adverse Reactions (6.1)</content>]. Uric acid fluctuations in patients with gout may precipitate an acute flare. The potential for uric acid elevation should be considered before administering sodium sulfate, potassium sulfate and magnesium sulfate oral solution to patients with gout or other disorders of uric acid metabolism.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID44">
                     <id root="48411a29-e336-4df8-82bc-1f6f7813711c"/>
                     <title>5.2 Cardiac Arrhythmias</title>
                     <text>
                        <paragraph ID="ID45">There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing sodium sulfate, potassium sulfate and magnesium sulfate oral solution for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID46">
                     <id root="0fbec6b3-f46c-4bc0-9936-de7fedb6acd0"/>
                     <title>5.3 Seizures</title>
                     <text>
                        <paragraph ID="ID47">There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.</paragraph>
                        <paragraph>Use caution when prescribing sodium sulfate, potassium sulfate and magnesium sulfate oral solution for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia <content styleCode="italics">[see Drug Interactions (7.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID48">
                     <id root="d152a0c1-38d4-44ef-ad39-e604ac5a6479"/>
                     <title>5.4 Use in Patients with Risk of Renal Injury</title>
                     <text>
                        <paragraph ID="ID49">Use sodium sulfate, potassium sulfate and magnesium sulfate oral solution with caution in patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs)<content styleCode="italics"> [see Drug Interactions (7.1)]</content>. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration with sodium sulfate, potassium sulfate and magnesium sulfate oral solution and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients <content styleCode="italics">[see Use in Specific Populations (8.6)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID50">
                     <id root="c7601584-eca5-472a-bd11-8e8a53a16649"/>
                     <title>5.5 Colonic Mucosal Ulcerations and Ischemic Colitis</title>
                     <text>
                        <paragraph ID="ID51">Osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and sodium sulfate, potassium sulfate and magnesium sulfate oral solution may increase these risks <content styleCode="italics">[see Drug Interactions (7.3)]</content>. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID52">
                     <id root="01e6c88d-1e65-473c-b3eb-4699dedd9f9e"/>
                     <title>5.6 Use in Patients with Significant Gastrointestinal Disease</title>
                     <text>
                        <paragraph ID="ID53">If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering sodium sulfate, potassium sulfate and magnesium sulfate oral solution. <content styleCode="italics">[see Contraindications (4)].</content>
                        </paragraph>
                        <paragraph>Use with caution in patients with severe active ulcerative colitis.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID54">
                     <id root="fe89dc9b-8cbd-4719-a02c-95ef48977362"/>
                     <title>5.7 Aspiration</title>
                     <text>
                        <paragraph ID="ID55">Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution. Observe these patients during administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution. Use with caution in these patients. </paragraph>
                     </text>
                     <effectiveTime value="20240117"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID56">
               <id root="d24cdb9b-74b8-4e2e-9526-1c7e3cf08a74"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID58">Most common adverse reactions are:</paragraph>
                        <list listType="unordered" ID="ID59" styleCode="Disc">
                           <item>Adults (&gt;2%): overall discomfort,      abdominal distention, abdominal pain, nausea, and vomiting. (6.1)</item>
                           <item>Pediatric Patients (&gt;10%): nausea, abdominal pain,      abdominal bloating and vomiting. (6.1)</item>
                        </list>
                        <paragraph ID="ID60">To report SUSPECTED ADVERSE REACTIONS, contact Strides Pharma Inc. at 1-877-244-9825 or FDA at 1-800-FDA-1088 or <content styleCode="bold">
                              <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID61">
                     <id root="7813e76f-573b-4e01-933a-96d3add34e05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph ID="ID62">The following important adverse reactions for bowel preparations are described elsewhere in the labeling:</paragraph>
                        <list listType="unordered" ID="ID63" styleCode="Disc">
                           <item>  Serious Fluid and Serum Chemistry Abnormalities <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                           </item>
                           <item>  Cardiac Arrhythmias <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                           </item>
                           <item>  Seizures <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                           </item>
                           <item>  Use in Patients with Risk of Renal Injury <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>
                           </item>
                           <item>  Colonic Mucosal Ulceration and Ischemic Colitis <content styleCode="italics">[see Warnings and Precautions (5.5)]</content>
                           </item>
                           <item>  Patients with Significant Gastrointestinal Disease<content styleCode="italics">[see Warnings and Precautions (5.6)]</content>
                           </item>
                           <item>  Aspiration <content styleCode="italics">[see Warnings and Precautions (5.7)]</content>
                              <content styleCode="italics">   </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID64">
                     <id root="a0eac281-c9ee-4244-b449-3fcb6e736122"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph ID="ID65">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>The safety of sodium sulfate, potassium sulfate and magnesium sulfate oral solution was evaluated in a multi-center, randomized, active controlled trial in 379 adult patients undergoing colonoscopy <content styleCode="italics">[see Clinical Studies (14)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Most Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Table 1 shows the most common adverse reactions reported in at least 2% of patients receiving sodium sulfate, potassium sulfate and magnesium sulfate oral solution or the control (a bowel prep containing polyethylene glycol and electrolytes (PEG + E)) administered in split-dose (2-day) regimens.</paragraph>
                        <table ID="ID66" width="100%" styleCode="Noautorules">
                           <caption>  Table 1: Common Adverse Reactions* in Adult Patients Undergoing Colonoscopy in a Randomized, Active Controlled Trial</caption>
                           <col width="113"/>
                           <col width="113"/>
                           <col width="113"/>
                           <col width="113"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>*</sup> reported in at least 2% of patients</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Lrule Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Symptom</content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule"/>
                                 <td colspan="2" valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                                    <content styleCode="bold"> Split-Dose (2-Day) Regimen</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>  %       <br/>      N=190<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + E product<br/> %<br/> N=189<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Overall Discomfort<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 54<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 67<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Distension<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 40<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 52<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Abdominal Pain<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 36<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 43<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Nausea<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 36<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 33<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Vomiting<br/>
                                 </td>
                                 <td colspan="2" valign="top" styleCode=" Botrule Rrule" align="center"> 8<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID67">
                           <content styleCode="italics">Laboratory Abnormalities</content>
                        </paragraph>
                        <paragraph>Table 2 shows the most common laboratory abnormalities (at least 10% in either treatment group and more than 2% difference between groups) for patients who developed new abnormalities of important electrolytes and uric acid after completing the bowel preparation with either sodium sulfate, potassium sulfate and magnesium sulfate oral solution or PEG+E administered as a split-dose (2-day) regimen.     </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 2: Adult Patients with Normal Baseline Serum Chemistry with A Shift to an Abnormal Value While on the Split-Dose (2-Day) Regimen</content> <sup>1</sup>
                        </paragraph>
                        <table ID="ID68" width="100%" styleCode="Noautorules">
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>1</sup>The study was not designed to support comparative claims for the laboratory abnormalities reported in this table. </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="4">
                                    <paragraph styleCode="Footnote">
                                       <sup>2</sup>Percent (n/N) of patients where N=number of patients with normal baseline who had abnormal values at the time point(s) of interest.</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode="Lrule Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Day of Colonoscopy        </content>
                                    <br/>
                                    <content styleCode="bold"> N (%)<sup>2</sup>
                                    </content>
                                    <br/>
                                 </td>
                                 <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold"> Day 30               </content>
                                    <br/>
                                    <content styleCode="bold"> N (%)<sup>2</sup>
                                    </content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Bicarbonate (low)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (13)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 7 (4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 24 (15)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (3)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Bilirubin, total (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 14 (9)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 0 (0)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (12)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 3 (2)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> BUN (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 2 (2)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 14 (11)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (3)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 19 (15)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Calcium (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 16 (10)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8 (5)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (4)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Chloride (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 4 (2)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (12)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 6 (4)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Osmolality (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 8 (6)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 19 (13)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> NA<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule" align="center"> Uric acid (high)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 27 (24)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 13 (12)<br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode="Lrule Botrule Rrule"/>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> PEG + Electrolytes<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 12 (10)<br/>
                                 </td>
                                 <td valign="top" styleCode=" Botrule Rrule" align="center"> 20 (17)<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="ID69">
                           <content styleCode="italics">Less Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>AV Block (1 case) and CK increase.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adverse Reactions with Unapproved Use</content>
                        </paragraph>
                        <paragraph>In another study of 408 adult patients, higher rates of the following adverse reactions and laboratory abnormalities were reported in patients treated with sodium sulfate, potassium sulfate and magnesium sulfate oral solution as an evening-only (1-day) regimen compared to the split-dose (2-day) regimen.</paragraph>
                        <list listType="unordered" ID="ID70" styleCode="Disc">
                           <item>overall discomfort, abdominal distention, nausea, and vomiting</item>
                           <item>total bilirubin (high), BUN (high), creatinine (high), osmolality (high), potassium (high) and uric acid (high)</item>
                        </list>
                        <paragraph ID="ID71">Administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in an evening-only (1-day) dosing regimen is not recommended.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatrics 12 Years to 16 Years of Age</content>
                        </paragraph>
                        <paragraph>The safety of sodium sulfate, potassium sulfate and magnesium sulfate oral solution was evaluated in a single dose-ranging clinical trial of 89 pediatric patients aged 12 years to 16 years <content styleCode="italics">[see Clinical Studies (14)]</content>. In 26 pediatric patients who received sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses), the most common adverse reactions (&gt; 10%) were nausea, abdominal pain, abdominal bloating, and vomiting.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID72">
               <id root="162651ed-5872-44e2-916d-4efb59a221e2"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20231208"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="ID74">Drugs that increase risk of fluid and electrolyte imbalance. (7.1)  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID75">
                     <id root="22c042bd-7fe1-4613-ac4c-abc73d65f342"/>
                     <title>7.1 Drugs That May Increase Risks of Fluid and Electrolyte Abnormalities</title>
                     <text>
                        <paragraph ID="ID76">Use caution when prescribing sodium sulfate, potassium sulfate and magnesium sulfate oral solution to patients taking medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities <content styleCode="italics">[see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)].</content> <content styleCode="italics">        </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID77">
                     <id root="237e00af-4244-4a33-bd34-f83621f34851"/>
                     <title>7.2 Potential for Reduced Drug Absorption</title>
                     <text>
                        <paragraph ID="ID78">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution can reduce the absorption of other co-administered drugs <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.       </paragraph>
                        <list listType="unordered" ID="ID79" styleCode="Disc">
                           <item>Administer oral medications at least      one hour before starting each dose of sodium sulfate, potassium sulfate      and magnesium sulfate oral solution.</item>
                           <item>Administer tetracycline and      fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, and      penicillamine at least 2 hours before and not less than 6 hours after      administration of sodium sulfate, potassium sulfate and magnesium sulfate      oral solution to avoid chelation with magnesium.</item>
                        </list>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID80">
                     <id root="bcefa359-5bcd-402c-ba16-5c09a4887689"/>
                     <title>7.3 Stimulant Laxatives</title>
                     <text>
                        <paragraph ID="ID81">Concurrent use of stimulant laxatives and sodium sulfate, potassium sulfate and magnesium sulfate oral solution may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution<content styleCode="italics"> [see Warnings and Precautions (5.5)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID82">
               <id root="caa26bb6-1686-4494-b46f-908c3af20621"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20231208"/>
               <component>
                  <section ID="ID83">
                     <id root="9ec85a51-aef1-4384-aefa-47966fc2e508"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="ID84">
                           <content styleCode="underline">Risk Summary﻿</content>
                        </paragraph>
                        <paragraph>There are no available data on sodium sulfate, potassium sulfate and magnesium sulfate oral solution use in pregnant women to evaluate for a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproductive studies have not been conducted with sodium sulfate, potassium sulfate, and magnesium sulfate (sodium sulfate, potassium sulfate and magnesium sulfate oral solution).</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID85">
                     <id root="72cba9b7-63ed-48c5-9ebf-f87e6e7b0261"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="ID86">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data available data on the presence of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in human or animal milk, the effects on the breastfed child, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for sodium sulfate, potassium sulfate and magnesium sulfate oral solution and any potential adverse effects on the breastfed child from sodium sulfate, potassium sulfate and magnesium sulfate oral solution or from the underlying maternal condition. </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID87">
                     <id root="250644a0-6c0a-424a-a58f-826d2832e5f9"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="ID88">The safety and effectiveness of sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) have been established for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older. Use of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in this age group is supported by evidence from an adequate and well-controlled trial of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in adults and a single, dose-ranging, controlled trial in 89 pediatric patients 12 years to 16 years of age <content styleCode="italics">[see Clinical Studies ( 14)] </content>. In the pediatric trial, sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 6-ounce doses) did not demonstrate additional treatment benefit and more patients reported gastrointestinal adverse reactions compared to sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses). Therefore, sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 6-ounce doses) is not recommended for pediatric patients 12 years of age and older <content styleCode="italics">[see Dosage and Administration (2.3)]</content>. The safety profile of sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) in this pediatric population was similar to that seen in adults <content styleCode="italics">[see Adverse Reactions (6.1)]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in pediatric patients less than 12 years of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID89">
                     <id root="acb5f2d4-404c-4247-9d1c-6f1ef9014b51"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="ID90">Of the 375 patients who received sodium sulfate, potassium sulfate and magnesium sulfate oral solution in clinical trials, 94 (25%) were 65 years of age or older, and 25 (7%) were 75 years of age or older. No overall differences in safety or effectiveness of sodium sulfate, potassium sulfate and magnesium sulfate oral solution administered as the recommended split-dose (2-day) regimen were observed between geriatric patients and younger patients. Geriatric patients reported more vomiting when sodium sulfate, potassium sulfate and magnesium sulfate oral solution was given as a one-day preparation (not a recommended regimen). Elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID91">
                     <id root="025d1f54-b9e2-4122-a980-322d59bc69fb"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph ID="ID92">Use sodium sulfate, potassium sulfate and magnesium sulfate oral solution with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after use of sodium sulfate, potassium sulfate and magnesium sulfate oral solution and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID93">
               <id root="e9ffea2e-56b3-4056-b358-bd91e0cb24b4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="ID94">Overdosage of more than the recommended dose of sodium sulfate, potassium sulfate and magnesium sulfate oral solution may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances. <content styleCode="italics">[see Warnings and Precautions (5.1, 5.2, 5.3)]</content>. Monitor for fluid and electrolyte disturbances and treat symptomatically.</paragraph>
               </text>
               <effectiveTime value="20231208"/>
            </section>
         </component>
         <component>
            <section ID="ID95">
               <id root="3cccc7e3-33bd-405d-afe4-eedc00ac1096"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="ID96">Sodium sulfate, potassium sulfate and magnesium sulfate oral solution <content styleCode="bold">(for adults) </content>is an osmotic laxative and is provided as two bottles each containing 6 ounces of solution. Each bottle contains: 17.5 grams sodium sulfate, 3.13 grams potassium sulfate, and 1.6 grams magnesium sulfate. Inactive ingredients include: citric acid monohydrate USP, mixberry flavor, malic acid USP-NF, purified water, sodium benzoate USP-NF, sucralose USP-NF.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Sodium Sulfate, USP</content>
                  </paragraph>
                  <paragraph>The chemical name is Na<sub>2</sub>SO<sub>4</sub>. The average Molecular Weight is 142.04. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph ID="ID98">
                     <content styleCode="underline">Potassium Sulfate, FCC, purified</content>
                  </paragraph>
                  <paragraph>The chemical name is K<sub>2</sub>SO<sub>4</sub>. The average Molecular Weight is 174.26. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph ID="ID100">
                     <content styleCode="underline">Magnesium Sulfate, USP</content>
                  </paragraph>
                  <paragraph>The chemical name is MgSO<sub>4</sub>. The average Molecular Weight: 120.37. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph ID="ID102">Each sodium sulfate, potassium sulfate and magnesium sulfate oral solution package also contains a polypropylene mixing container.</paragraph>
               </text>
               <effectiveTime value="20240117"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Sodium Sulfate</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="04d878ff-5de5-484f-bbe0-18550e669656-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Potassium Sulfate</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="04d878ff-5de5-484f-bbe0-18550e669656-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM3">
                     <text>Magnesium Sulfate</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="04d878ff-5de5-484f-bbe0-18550e669656-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID103">
               <id root="6e981056-3c71-4f6c-b01c-49fd0fbf4ea8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20231208"/>
               <component>
                  <section ID="ID104">
                     <id root="5cd87ac1-1e03-41e7-a540-51760da3d8f6"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="ID105">Sulfate salts provide sulfate anions, which are poorly absorbed. The osmotic effect of unabsorbed sulfate anions and the associated cations causes water to be retained within the gastrointestinal tract.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID106">
                     <id root="872da00f-fbac-49d8-b109-0b0b142d9443"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="ID107">No formal pharmacodynamic studies have been conducted with sodium sulfate, potassium sulfate and magnesium sulfate oral solution. </paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
               <component>
                  <section ID="ID108">
                     <id root="70a839b2-10f5-4713-ab23-8f5c23f3fb60"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="ID109">
                           <content styleCode="underline">Absorption and Elimination</content>
                        </paragraph>
                        <paragraph>After administration of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in six healthy subjects, the time at which serum sulfate reached its highest point (T<sub>max</sub>) was approximately 17 hours after the first dose or approximately 5 hours after the second dose, and then declined with a half-life of 8.5 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Fecal excretion was the primary route of sulfate elimination.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>The disposition of sulfate after ingestion of sodium sulfate, potassium sulfate and magnesium sulfate oral solution was studied in patients (N=6) with moderate renal impairment (creatinine clearance of 30 to 49 mL/min). In patients with moderate renal impairment, mean AUC was 54% higher and mean C<sub>max</sub> was 44% higher, than healthy subjects.</paragraph>
                        <paragraph>The mean sulfate concentrations in healthy subjects and in patients with moderate renal impairment returned to their respective baselines by Day 6 after dose initiation. Urinary excretion of sulfate over 30 hours after the first dose was approximately 16% lower in patients with moderate renal impairment than in healthy subjects. These differences are not considered clinically meaningful.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The disposition of sulfate after ingestion of sodium sulfate, potassium sulfate and magnesium sulfate oral solution was studied in patients (N=6) with mild to moderate hepatic impairment (Child-Pugh grades A and B). Systemic exposure of serum sulfate (AUC and C<sub>max</sub>) was similar between healthy subjects and patients with hepatic impairment. The mean sulfate concentrations in healthy subjects and in patients with mild to moderate hepatic impairment returned to their respective baselines by Day 6 after dose initiation. Urinary excretion of sulfate over 30 hours after the first dose was similar between patients with hepatic impairment and healthy subjects.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID110">
               <id root="0a5f63d8-d581-4a73-90a8-fcd8904b7020"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20231208"/>
               <component>
                  <section ID="ID111">
                     <id root="21cca598-0ebe-44c5-a2f9-1cba80b3474e"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph ID="ID112">The sulfate salts of sodium, potassium, and magnesium contained in sodium sulfate, potassium sulfate and magnesium sulfate oral solution were administered orally (gavage) to rats and dogs up to 28 days up to a maximum daily dose of 5 grams/kg/day (approximately 0.9 and 3 times for rats and dogs, respectively, the recommended human dose of 44 grams/day or 0.89 grams/kg based on the body surface area). In rats, the sulfate salts caused diarrhea and electrolyte and metabolic changes, including hypochloremia, hypokalemia, hyponatremia, lower serum osmolality, and high serum bicarbonate. Significant renal changes included increased fractional sodium excretion, increased urinary sodium and potassium excretion, and alkaline urine in both males and females. In addition, creatinine clearance was significantly decreased in females at the highest dose. No microscopic renal changes were seen. In dogs, the sulfate salts caused emesis, excessive salivation, excessive drinking of water, and abnormal excreta (soft and/or mucoid feces and/or diarrhea) and increased urine pH and sodium excretion.</paragraph>
                     </text>
                     <effectiveTime value="20231208"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID113">
               <id root="4bdfaab4-4289-40bc-abf9-9a479abd3bb8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="ID114">
                     <content styleCode="underline">Adults</content>
                  </paragraph>
                  <paragraph>The colon cleansing efficacy of sodium sulfate, potassium sulfate and magnesium sulfate oral solution was evaluated in a randomized, single- blind, active-controlled, multicenter study in adult patients scheduled to have a colonoscopy. There were 363 adult patients included in the efficacy analysis. Patients ranged in age from 20 to 84 years (mean age 55 years) and 54% were female. Race distribution was 86% Caucasian, 9% African-American, and 5% other.</paragraph>
                  <paragraph>Patients were randomized to one of the following two colon preparation regimens: sodium sulfate, potassium sulfate and magnesium sulfate oral solution or a marketed polyethylene glycol (PEG) plus electrolytes bowel preparation. In the Study sodium sulfate, potassium sulfate and magnesium sulfate oral solution was administered as a split-dose (two-day) regimen. The PEG bowel prep was also given as a split-dose preparation according to its labeled instructions. Patients receiving sodium sulfate, potassium sulfate and magnesium sulfate oral solution were limited to a light breakfast followed by clear liquids on the day prior to the day of colonoscopy; patients receiving the PEG bowel prep were allowed to have a normal breakfast and a light lunch, followed by clear liquids.</paragraph>
                  <paragraph>The primary efficacy endpoint was the proportion of patients with successful colon cleansing as assessed by the colonoscopists, who were not informed about the type of preparation received, as shown in Table 3. In the study, no clinically or statistically significant differences were seen between the group treated with sodium sulfate, potassium sulfate and magnesium sulfate oral solution and the group treated with the PEG bowel prep.</paragraph>
                  <table ID="ID115" width="100%" styleCode="Noautorules">
                     <caption>  Table 3: Proportion of Adult Patients with Successful Colon Cleansing Response Rates </caption>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">
                                 <sup>1</sup> Responders were patients whose colon preparations were graded excellent (no more than small bits of adherent feces/fluid) or good (small amounts of feces or fluid not interfering with the exam) by the colonoscopist.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">
                                 <sup>2</sup> Does not equal difference in tabled responder rates due to rounding effects.</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="bottom" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Treatment Group</content>
                              <br/>
                           </td>
                           <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Regimen</content>
                              <br/>
                           </td>
                           <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Responders<sup>1</sup>
                              </content>
                              <br/>
                              <content styleCode="bold"> %</content>
                              <br/>
                              <content styleCode="bold"> (95% C. I.)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="center">
                              <content styleCode="bold"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution – PEG Difference</content>
                              <br/>
                              <content styleCode="bold"> (95% CI)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution (With light breakfast)<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> Split-Dose<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 180<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center">
                              <content styleCode="bold"> 97%</content>
                              <br/> (94%, 99%)  <br/>
                           </td>
                           <td rowspan="2" styleCode=" Botrule Rrule" align="center">
                              <content styleCode="bold"> 2%<sup>2</sup>
                              </content>
                              <br/> (-2%, 5%)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left"> PEG bowel prep<br/> (with normal breakfast &amp; light lunch)<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> Split-Dose<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="center"> 183<br/>
                           </td>
                           <td valign="top" styleCode=" Botrule Rrule" align="center">
                              <content styleCode="bold"> 96%</content>
                              <br/> (92%, 98%)<br/>          <br/>    <br/>     <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID161">
                     <content styleCode="underline">Pediatric Patients 12 Years to 16 Years of Age</content>
                  </paragraph>
                  <paragraph>Sodium sulfate, potassium sulfate and magnesium sulfate oral solution was evaluated for colon cleansing in a randomized, single-blind, multicenter, dose ranging, active-controlled study in 89 pediatric patients 12 years to 16 years of age. The majority of patients were female (57%), white (78%), and of non-Hispanic or non-Latino ethnicity (91%). The mean age was 14 years. The median body weight was 60 kg (range 32 to 155 kg).</paragraph>
                  <paragraph>Patients were randomized to sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 6-ounce doses), sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) or oral PEG solution. sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 6-ounce doses) did not demonstrate additional treatment benefit and more patients reported gastrointestinal adverse reactions compared to sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses); therefore, sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 6-ounce doses) is not recommended for pediatric patients 12 years of age and older <content styleCode="italics">[see Dosage and Administration (2.4)]</content>.</paragraph>
                  <paragraph>Patients in the sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) group took the preparation in a "split-dose" regimen, where the first dose was taken the evening before colonoscopy, with the second dose taken the morning of the exam. Patients in the control group took the preparation according to its approved labeling on the evening before colonoscopy.</paragraph>
                  <paragraph>Patients in the sodium sulfate, potassium sulfate and magnesium sulfate oral solution group (two 4.5-ounce doses) were allowed to have a light breakfast on the day before colonoscopy, followed by clear liquids until the colonoscopy is completed the following day. Patients in the control group subjects were permitted only clear liquids on the day prior to colonoscopy until completion of the colonoscopy the following day. </paragraph>
                  <paragraph>The primary efficacy endpoint was the proportion of patients with successful colon cleansing as assessed by the colonoscopists, who were not informed about the type of preparation received.</paragraph>
                  <paragraph>The percentage of responders and the associated 95% confidence intervals for the sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) and Oral PEG solution are shown in Table 4. Efficacy was similar between patients who weighed 65 kg or more (n=12) and those patients who weighed less than 65 kg (n=15) in the sodium sulfate, potassium sulfate and magnesium sulfate oral solution (two 4.5-ounce doses) arm.</paragraph>
                  <table ID="ID162" width="100%" styleCode="Noautorules">
                     <caption>  Table 4: Proportion of Pediatric Patients 12 Years to 16 Years of Age with Successful Colon Cleansing Response Rates </caption>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">
                                 <sup>1</sup>Responders were patients whose colon preparations were graded excellent (no more than small bits of adherent feces/fluid) or good (small amounts of feces or fluid not interfering with the exam) by the colonoscopist.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" colspan="5">
                              <paragraph styleCode="Footnote">
                                 <sup>2</sup>Does not equal difference in tabled responder rates due to rounding effects.</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td valign="bottom" styleCode="Lrule Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Treatment Group</content>
                              <br/>
                           </td>
                           <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Regimen</content>
                              <br/>
                           </td>
                           <td valign="bottom" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> N</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Responders<sup>1</sup>
                              </content>
                              <br/>
                              <content styleCode="bold"> %</content>
                              <br/>
                              <content styleCode="bold"> (95% C. I.)</content>
                              <br/>
                           </td>
                           <td valign="top" styleCode=" Toprule Botrule Rrule" align="left">
                              <content styleCode="bold"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution – PEG Difference</content>
                              <br/>
                              <content styleCode="bold"> (95% CI)</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution 4.5 ounces per dose (with light breakfast)<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Split-Dose<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> 26<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left">
                              <content styleCode="bold"> 85%</content>
                              <br/> (71%, 99%)<br/>
                           </td>
                           <td rowspan="2" styleCode=" Botrule Rrule" align="left">
                              <content styleCode="bold"> 25</content> % <sup>2</sup>
                              <br/> (3%, 47%)<br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Botrule Rrule" align="left"> Oral PEG solution (with clear liquids only)<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> Evening Dosing<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left"> 32<br/>
                           </td>
                           <td styleCode=" Botrule Rrule" align="left">
                              <content styleCode="bold"> 59</content> %<br/> (42%, 76%)<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20231208"/>
            </section>
         </component>
         <component>
            <section ID="ID116">
               <id root="ed3ca8a8-5f2d-45e0-bbd9-464e5aa4df1a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph ID="ID117">Each sodium sulfate, potassium sulfate and magnesium sulfate oral solution <content styleCode="bold">(for adults) </content>(NDC 64380-116-01) contains:</paragraph>
                  <list listType="unordered" ID="ID118" styleCode="Disc">
                     <item>Two bottles (NDC 64380-116-02) each containing 6-ounces of an oral solution of 17.5 grams sodium sulfate, 3.13 grams potassium sulfate, and 1.6 grams magnesium sulfate as a clear to slightly hazy liquid. When diluted as directed, the solution is clear and colorless.</item>
                     <item>One (1) mixing container with a 16-ounce fill line.</item>
                  </list>
                  <paragraph ID="ID153">Store at 20° to 25°C (68° to 77°F). Excursions permitted between 15° to 30°C (59° to 86°F). See USP controlled room temperature.</paragraph>
               </text>
               <effectiveTime value="20240604"/>
            </section>
         </component>
         <component>
            <section ID="ID136">
               <id root="97baa2da-3d30-45d3-805b-704e51d46929"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph ID="ID145">Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>Instruct patients or caregivers:</paragraph>
                  <list listType="unordered" ID="ID146" styleCode="Disc">
                     <item>Must dilute sodium sulfate, potassium      sulfate and magnesium sulfate oral solution before ingestion.</item>
                     <item>Must consume additional water after each dose of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution.</item>
                     <item>On the day before colonoscopy, consume only a light      breakfast or clear liquids (e.g., water, apple or orange juice without      pulp, lemonade, coffee, tea, or chicken broth). On the day of the      colonoscopy only consume clear liquids up to two hours prior to      colonoscopy.</item>
                     <item>Two doses of sodium sulfate, potassium      sulfate and magnesium sulfate oral solution are      required for a complete preparation for colonoscopy. One bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution is equivalent to one dose.</item>
                     <item>Do not to take other laxatives while taking sodium sulfate, potassium sulfate and magnesium sulfate oral      solution.</item>
                     <item>Do not eat solid food or drink milk or eat or drink      anything colored red or purple.</item>
                     <item>Do not drink alcohol.</item>
                     <item>Do not take oral medications within one hour of starting      each dose of sodium sulfate, potassium sulfate and      magnesium sulfate oral solution.</item>
                     <item>If taking tetracycline or fluoroquinolone antibiotics,      iron, digoxin, chlorpromazine, or penicillamine, take these medications at      least 2 hours before and not less than 6 hours after administration of sodium sulfate, potassium sulfate and magnesium sulfate oral      solution <content styleCode="italics">[see Drug Interactions      (7.2)]</content> .</item>
                     <item>Stop consumption of all fluids at least 2 hours prior to      colonoscopy.</item>
                     <item>Contact their healthcare provider if they develop      significant vomiting or signs of dehydration after taking sodium sulfate, potassium sulfate and magnesium sulfate oral      solution or if they experience cardiac arrhythmias or seizures <content styleCode="italics">[see      Warnings and Precautions (5.1, 5.2, 5.3)].</content>
                     </item>
                  </list>
                  <paragraph ID="ID147">Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Science Limited                                                                </content>
                  </paragraph>
                  <paragraph>Bengaluru – 562106, India.</paragraph>
                  <paragraph>           </paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Strides Pharma Inc.</content>
                  </paragraph>
                  <paragraph>East Brunswick, NJ 08816.</paragraph>
                  <paragraph>Revised: 10/2023</paragraph>
               </text>
               <effectiveTime value="20240117"/>
            </section>
         </component>
         <component>
            <section ID="ID121">
               <id root="336f485e-54ef-4bec-9a02-1c79622587d0"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="ID122" width="100%" styleCode="Noautorules">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Lrule Toprule Rrule" align="center">
                              <content styleCode="bold"> MEDICATION GUIDE</content>
                              <br/>
                              <content styleCode="bold"> Sodium Sulfate (soe' dee um sul' fate), Potassium Sulfate (poe tas ' ee um sul' fate) and Magnesium Sulfate ( mag nee' zee um sul' fate) Oral Solution</content>
                              <br/>
                              <content styleCode="bold">          </content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left"> Read and understand this Medication Guide instructions <content styleCode="bold"> at least 2 days before</content>  your colonoscopy and again before you start taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution.          <br/>     <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> What is the most important information I should know about sodium sulfate, potassium sulfate and magnesium sulfate oral solution?</content>
                              <br/>
                              <content styleCode="bold"> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution and other bowel preparations can cause serious side effects, including:</content>
                              <br/> •  <content styleCode="bold"> Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause:</content>
                              <br/> •  <content styleCode="bold"> abnormal heartbeats that can cause death </content>
                              <br/>        • <content styleCode="bold"> seizures. </content> This can happen even if you have never had a seizure.<br/>        • <content styleCode="bold"> kidney problems</content>
                              <br/>
                              <br/>
                              <content styleCode="bold"> Your chance of having fluid loss and changes in body salts with sodium sulfate, potassium sulfate and magnesium sulfate oral solution is higher if you:</content>
                              <br/> •  have heart problems<br/> •  have kidney problems<br/> •  take water pills or non-steroidal anti-inflammatory drugs (NSAIDS)<br/>
                              <content styleCode="bold"> Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution:</content>
                              <br/> •  vomiting <br/> •  dizziness<br/> •  urinating less often than normal<br/> •  headache     <br/>
                              <content styleCode="bold"> See What are the possible side effects of sodium sulfate, potassium sulfate and magnesium sulfate oral solution? for more information about side effects.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> What is sodium sulfate, potassium sulfate and magnesium sulfate oral solution?</content>
                              <br/> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution is a prescription medicine used by adults and children 12 years of age and older to clean the colon before a colonoscopy. Sodium sulfate, potassium sulfate and magnesium sulfate oral solution cleans your colon by causing you to have diarrhea. Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.<br/>
                              <br/>
                              <content styleCode="bold"> It is not known if sodium sulfate, potassium sulfate and magnesium sulfate oral solution is safe and effective in children under 12 years of age.</content>
                              <br/>
                              <content styleCode="bold"> Do not</content>  take sodium sulfate, potassium sulfate and magnesium sulfate oral solution if your healthcare provider has told you that you have:<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left"> •   a blockage in your intestine (bowel obstruction)<br/> •   an opening in the wall of your stomach or intestine (bowel perforation)<br/> •   a very dilated intestine (toxic megacolon)<br/> •   problems with the emptying of food and fluid from your stomach (gastric retention)<br/> •   an allergy to any of the ingredients in sodium sulfate, potassium sulfate and magnesium sulfate oral solution. See the end of this Medication Guide   for a complete list of ingredients in sodium sulfate, potassium sulfate and magnesium sulfate oral solution.<br/>      <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> Before taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/> •   have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes).<br/> •   have gout<br/> •   have heart problems including an irregular heartbeat, especially a condition called "QT prolongation".<br/> •   have a history of seizures or take medicines for seizures.<br/> •   are withdrawing from drinking alcohol or from taking benzodiazepines.<br/> •   have a low blood salt (sodium) level.<br/> •   have kidney problems or take medicines for kidney problems.<br/> •   have stomach or bowel problems including ulcerative colitis.<br/> •   have problems with swallowing or gastric reflux.<br/> •   are pregnant or plan to become pregnant. It is not known if sodium sulfate, potassium sulfate and magnesium sulfate oral solution will harm your unborn baby. Talk to your healthcare provider if you are pregnant.<br/> •   are breastfeeding or plan to breastfeed. It is not known if sodium sulfate, potassium sulfate and magnesium sulfate oral solution passes into your breast milk. You and your healthcare provider should decide if you will take sodium sulfate, potassium sulfate and magnesium sulfate oral solution while breastfeeding.<br/>     <br/>      <br/>
                              <content styleCode="bold"> Tell your healthcare provider about all the medicines you take, </content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br/> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of each dose of sodium sulfate, potassium sulfate and magnesium sulfate oral solution.<br/>             <br/>   <content styleCode="bold"> Especially tell your healthcare provider if you take:</content>
                              <br/> •   medicines for blood pressure or heart problems.<br/> •   medicines for kidney problems.<br/> •   medicines for seizures.<br/> •   water pills (diuretics).<br/> •   non-steroidal anti-inflammatory medicines (pain medicines).<br/> •   medicines for depression or mental health problems.<br/> •   laxatives. <content styleCode="bold"> Do not </content> take other laxatives while taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution.<br/> The following medicines should be taken at least 2 hours before starting sodium sulfate, potassium sulfate and magnesium sulfate oral solution and not less than 6 hours after taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution:<br/>       <br/> •   tetracycline<br/> •   fluoroquinolone antibiotics<br/> •   iron<br/> •   digoxin (Lanoxin)<br/> •   chloropromazine<br/> •   penicillamine (Cuprimine. Depen)<br/> Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above.<br/> Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> How should I take sodium sulfate, potassium sulfate and magnesium sulfate oral solution?</content>
                              <br/>
                              <content styleCode="bold"> See the Instructions for Use in the Patient Instructions for Use Booklet for dosing instructions. You must read, understand, and follow these instructions to take sodium sulfate, potassium sulfate and magnesium sulfate oral solution the right way.</content>
                              <br/> •   Take sodium sulfate, potassium sulfate and magnesium sulfate oral solution exactly as your healthcare provider tells you to take it.<br/> •   Each bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral solution must be mixed with water (diluted) before drinking.<br/> •   It is important for you to drink the additional prescribed amount of water listed in the Instructions for Use to prevent fluid loss (dehydration).<br/> •   One bottle of sodium sulfate, potassium sulfate and magnesium sulfate oral solution is equal to one dose.<br/> •   Two doses of sodium sulfate, potassium sulfate and magnesium sulfate oral solution are required for complete colonoscopy preparation.<br/> •   All people taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution should follow these general instructions starting 1 day <content styleCode="bold"> before</content>  your colonoscopy:<br/>    • eat only a light breakfast or clear liquids (for example: water, strained fruit juice without pulp, lemonade, plain coffee or tea, chicken broth, gelatin dessert without fruit) on the day before  your procedure.<br/>       • only drink clear liquids the rest of the day and the next day until 2 hours before your colonoscopy. <content styleCode="bold"> Stop</content>  drinking all fluids at least 2 hours before your colonoscopy.<br/>       • after taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution if you have any bloating or feeling like your stomach is upset, wait to take your second dose until your stomach feels better.<br/>         <br/>   <br/> •   <content styleCode="bold"> While taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution, do not:</content>
                              <br/>           • take any other laxatives.<br/>           • take any medicines by mouth (oral) within 1 hour of starting sodium sulfate, potassium sulfate and magnesium sulfate oral solution.<br/>           • eat solid foods, drink dairy (such as milk), or drink alcohol while taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution and until after your colonoscopy<br/>           • eat or drink anything colored red or purple.<br/>       <br/>
                              <content styleCode="bold"> Contact your healthcare provider right away </content> if after taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution you have severe vomiting, signs of dehydration, changes in consciousness such as feeling confused, delirious or fainting (loss of consciousness) or seizures after taking sodium sulfate, potassium sulfate and magnesium sulfate oral solution. <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> What are the possible side effects of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution?</content>
                              <br/> Sodium sulfate, potassium sulfate and magnesium sulfate oral solution can cause serious side effects, including:<br/> •   See<content styleCode="bold">  "What is the most important information I should know about sodium sulfate, potassium sulfate and magnesium sulfate oral solution?"</content>
                              <br/> •   <content styleCode="bold"> Changes in certain blood tests. </content> Your healthcare provider may do blood tests after you take sodium sulfate, potassium sulfate and magnesium sulfate oral solution to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:<br/>           •  vomiting<br/>           •   nausea<br/>           •   bloating<br/>           •  dizziness<br/>           •  stomach area (abdomen) cramping<br/>           •   headache<br/>           •  urinate less than usual<br/>           •  trouble drinking clear liquid<br/>           •  trouble swallowing<br/>           •  seizures<br/>           •  heart problems<br/>           •  worsening gout<br/>     <br/> •  <content styleCode="bold"> Ulcers of the bowel problems (ischemic colitis).</content>  Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding.<br/>      The most common side effects of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in adults include:<br/>          •   overall discomfort<br/>          •  stomach bloating<br/>          •  stomach pain <br/>          •  nausea<br/>          •  vomiting <br/>     The most common side effects of sodium sulfate, potassium sulfate and magnesium sulfate oral solution in children 12 to 16 years of age include:<br/>            •   nausea<br/>            •  stomach bloating<br/>            •  stomach pain <br/>          •  vomiting<br/> These are not all the possible side effects of sodium sulfate, potassium sulfate and magnesium sulfate oral solution.<br/> Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode=" Lrule Rrule" align="left">
                              <content styleCode="bold"> How should I store sodium sulfate, potassium sulfate and magnesium sulfate oral solution?</content>
                              <br/> •  Store sodium sulfate, potassium sulfate and magnesium sulfate oral solution at room temperature, between 68ºF to 77°F (20ºC to 25°C).<br/>
                              <content styleCode="bold"> Keep sodium sulfate, potassium sulfate and magnesium sulfate oral solution and all medicines out of the reach of children.</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Lrule Botrule Rrule" align="left">
                              <content styleCode="bold"> General information about the safe and effective use of sodium sulfate, potassium sulfate and magnesium sulfate oral solution.</content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use sodium sulfate, potassium sulfate and magnesium sulfate oral solution for a condition for which it was not prescribed. Do not give sodium sulfate, potassium sulfate and magnesium sulfate oral solution to other people, even if they are going to have the same procedure you are. It may harm them. You can ask your pharmacist or healthcare provider for information about sodium sulfate, potassium sulfate and magnesium sulfate oral solution that is written for healthcare professionals.<br/>
                              <content styleCode="bold"> What are the ingredients in sodium sulfate, potassium sulfate and magnesium sulfate oral solution?</content>
                              <br/> sodium sulfate, potassium sulfate and magnesium sulfate oral solution is supplied in two dosage strengths. Sodium sulfate, potassium sulfate and magnesium sulfate oral solution comes in a carton containing two 6-ounce bottles, along with a 16-ounce polypropylene mixing container.<br/> Each bottle contains:<br/>
                              <content styleCode="bold"> Active ingredients: </content> sodium sulfate, potassium sulfate and magnesium sulfate.<br/>
                              <content styleCode="bold"> Inactive ingredients: </content> citric acid monohydrate USP, mixberry flavor, malic acid USP-NF, purified water, sodium benzoate USP-NF, sucralose USP-NF.<br/>  Manufactured by:<br/>
                              <content styleCode="bold"> Strides Pharma Science Limited                                                                </content>
                              <br/> Bengaluru – 562106, India.<br/>            <br/> Distributed by:<br/>
                              <content styleCode="bold"> Strides Pharma Inc.</content>
                              <br/> East Brunswick, NJ 08816.<br/>       <br/> For more information, go to www.strides.com or call Strides Pharma Inc. at 1-877-244-9825.<br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="ID123">This Medication Guide has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Revised: 10/2023          </paragraph>
               </text>
               <effectiveTime value="20240604"/>
            </section>
         </component>
         <component>
            <section ID="ID124">
               <id root="a1ca9832-ae86-42f8-a82c-435da1394abc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph ID="ID125">NDC: 64380-116-01</paragraph>
                  <paragraph>177 ml Bottle Pack</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (17.5 g/3.13 g/1.6 g) per 6 ounces</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed Medication Guide to each patient.</paragraph>
                  <paragraph>For Adults</paragraph>
                  <paragraph>
                     <content styleCode="bold">This carton contains:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2 6-ounce (177 mL) bottles of liquid bowel prep</content>
                  </paragraph>
                  <paragraph>1 16-ounce mixing container</paragraph>
                  <paragraph>Medication Guide</paragraph>
                  <paragraph>Patient Instructions</paragraph>
                  <paragraph>Full Prescribing Information</paragraph>
                  <paragraph>
                     <content styleCode="bold">Recommended Dosage:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">See prescribing information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dilute the solution concentrate as directed prior to use.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Both 6-ounce bottles are required for a complete prep.</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Distributed by: <content styleCode="bold">Strides Pharma Inc.</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
                  <paragraph ID="ID148">NDC: 64380-116-02</paragraph>
                  <paragraph>177 ml Bottle Pack</paragraph>
                  <paragraph>
                     <content styleCode="bold">Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (17.5 g/3.13 g/1.6 g) per 6 ounces</content>
                  </paragraph>
                  <paragraph>Dispense the enclosed Medication Guide to each patient.</paragraph>
                  <paragraph>For Adults</paragraph>
                  <paragraph>This bottle contains 6 ounces (177 mL) of liquid bowel prep</paragraph>
                  <paragraph>
                     <content styleCode="bold">Directions:</content>
                  </paragraph>
                  <paragraph>Dilute the solution concentrate prior to use. See enclosed prescribing information for complete dosage and administration instructions. </paragraph>
                  <paragraph>Both 6-ounce bottles are required for a complete prep.</paragraph>
                  <paragraph>      </paragraph>
                  <paragraph>Keep this and other drugs out of reach of children.</paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Distributed by: <content styleCode="bold">Strides Pharma Inc.</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20240117"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Carton Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="04d878ff-5de5-484f-bbe0-18550e669656-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Container Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="04d878ff-5de5-484f-bbe0-18550e669656-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>